| NHBS*N % (95% CI) | SFCC*N % (95% CI) | ||
|---|---|---|---|
| TOTAL | 510 | 100.0% | 100.0% |
| AGE | |||
| 29 OR YOUNGER | 146 | 28.6% (24.7–32.8) | 31.9% (29.7–34.1) |
| 30–39 | 134 | 26.3% (22.5–30.3) | 31.7% (29.6–33.9) |
| 40–49 | 120 | 23.5% (19.9–27.5) | 24.1% (22.2–26.2) |
| 50 OR OLDER | 110 | 21.6% (18.1–25.4) | 12.3% (10.8–13.9) |
| RACE/ETHNICITY | |||
| WHITE | 300 | 59.1% (54.6–63.4) | 51.1% (48.7–53.4) |
| HISPANIC | 99 | 19.5% (16.1–23.2) | 22.5% (20.6–24.5) |
| AFRICAN AMERICAN | 31 | 6.1% (4.2–8.6) | 12.6% (11.1–14.2) |
| ASIAN | 37 | 7.3% (5.2–9.9) | 10.7% (9.3–12.2) |
| MULTIPLE | 26 | 5.1% (3.4–7.4) | 2.0% (1.4–2.8) |
| NATIVE AMERICAN | 9 | 1.8% (0.8–3.3) | 0.4% (0.1–0.9) |
| PACIFIC ISLANDER | 6 | 1.2% (0.4–2.6) | 0.3% (0.09–0.6) |
| OTHER | 0 | - | 0.4% (0.2–0.9) |
| INSURED (Aug 1 through Dec 19) | |||
| NO | 110 | 24.1% (20.3–28.3) | 57.1% (54.5–59.6) |
| YES | 346 | 75.9% (71.7–79.7) | 42.9% (40.4–45.5) |
| NON-INJECTION METH USE (PAST YEAR) | |||
| NO | 446 | 88.0% (84.8–90.7) | 91.5% (90.0–92.8) |
| YES | 61 | 12.0% (9.3–15.2) | 8.5% (7.2–10.0) |
| NON-INJECTION CRACK USE (PAST YEAR) | |||
| NO | 487 | 96.1% (94.0–97.6) | 98.9% (98.2–99.3) |
| YES | 20 | 3.9% (2.4–6.0) | 1.1% (0.7–1.8) |
| NON-INJECTION COCAINE USE (PAST YEAR) | |||
| NO | 381 | 75.1% (71.1–78.9) | 90.3% (88.7–91.7) |
| YES | 126 | 24.9% (21.1–28.9) | 9.7% (8.3–11.3) |
| NON-INJECTION POPPERS USE (PAST YEAR) | |||
| NO | 381 | 75.1% (71.1–78.9) | 88.9% (87.2–90.5) |
| YES | 126 | 24.9% (21.1–28.9) | 11.1% (9.5–12.8) |
| NON-INJECTION ERECTILE DYSFUNCTION DRUG USE (PAST YEAR) | |||
| NO | 393 | 77.5% (73.6–81.1) | 91.9% (90.4–93.2) |
| YES | 114 | 22.5% (18.9–26.4) | 8.1% (6.8–9.6) |
| NUMBER OF MALE SEX PARTNERS (PAST YEAR) | |||
| 0 | 40 | 7.8% (5.7–10.5) | 23.7% (21.5–26.0) |
| 1 | 80 | 15.7% (12.6–19.1) | 6.7% (5.4–8.1) |
| 2–5 | 162 | 31.8% (27.7–36.0) | 26.4% (24.1–28.8) |
| > = 6 | 228 | 44.7% (40.3–49.1) | 43.3% (40.7–45.9) |
| EVER TESTED FOR HIV | |||
| NO | 14 | 2.8% (1.5–4.6) | 4.6% (3.7–5.7) |
| YES | 493 | 97.2% (95.4–98.5) | 95.4% (94.3–96.3) |
| HIV POSITIVE PRIOR TO NHBS/SFCC VISIT | |||
| NO | 373 | 77.2% (73.2–80.9) | 81.6% (79.8–83.4) |
| YES | 110 | 22.8% (19.1–26.8) | 18.4% (16.6–20.2) |
| AMONG HIV POSITIVES: CURRENTLY ON HAART | |||
| NO | 12 | 11.0% (5.8–18.4) | 17.0% (11.7–23.4) |
| YES | 97 | 89.0% (81.6–94.2) | 83.0% (76.6–88.3) |
| AMONG HIV NEGATIVES: PEP USE (PAST YEAR) | |||
| NO | 359 | 96.2% (93.8, 97.9) | 96.3% (95.2–97.2) |
| YES | 14 | 3.8% (2.1–6.2) | 3.7% (2.8–4.8) |
| AMONG HIV NEGATIVES: HIV TEST (PAST 6 MONTHS) | |||
| NO | 176 | 47.2% (42.0–52.4) | 39.3% (36.5–42.2) |
| YES | 197 | 52.8% (47.6–58.0) | 60.7% (57.8–63.5) |
| CHLAMYDIA (PAST YEAR) | |||
| NO | 468 | 93.0% (90.4–95.1) | 87.8% (86.2–89.3) |
| YES | 35 | 7.0% (4.9–9.5) | 12.2% (10.7–13.8) |
| GONORRHEA (PAST YEAR) | |||
| NO | 458 | 90.7% (87.8–93.1) | 88.6% (87.0–90.0) |
| YES | 47 | 9.3% (6.9–12.2) | 11.4% (10.0–13.0) |
| SYPHILIS (PAST YEAR) | |||
| NO | 494 | 97.8% (96.1–98.9) | 95.2% (94.1–96.1) |
| YES | 11 | 2.2% (1.1–3.9) | 4.8% (3.9–5.9) |
↵* Column totals do not sum to sample totals because of missing values.